FDA to decide on Sanofi/Regeneron’s Dupixent for COPD in June

23 Feb 2024
www.pharmaceutical-technology.com
Drug ApprovalPhase 3Clinical ResultPriority ReviewOrphan Drug
FDA to decide on Sanofi/Regeneron’s Dupixent for COPD in June
Preview
Source: Pharmaceutical Technology
Dupixent is approved by the FDA in five indications namely atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis. Image Credit: SewCreamStudio/ Shutterstock.
Sanofi and Regeneron are close to adding chronic obstructive pulmonary disease (COPD) as the sixth indication for its blockbuster therapy Dupixent (dupilumab).
The US Food and Drug Administration (FDA) has granted priority review for a supplemental biologics licence application (sBLA) for Dupixent as an add-on maintenance treatment for certain adult patients with uncontrolled COPD. The agency has set a target date of 27 June 2024.
Dupixent, a monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, is already approved to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis.
As per Regeneron’s financials, Dupixent pulled in $11.59bn in global sales in 2023. GlobalData forecasts the therapy revenue to maintain its upward trajectory and generate $20.4bn in sales in 2030.
GlobalData is the parent company of Pharmaceutical Technology.
See Also:FDA generic drug approvals rose in 2023 in bid for improved access
FDA to decide on Sanofi/Regeneron’s Dupixent for COPD in June
Preview
Source: Pharmaceutical Technology
Immune-Onc’s antibody therapy collects second FDA orphan designation
FDA to decide on Sanofi/Regeneron’s Dupixent for COPD in June
Preview
Source: Pharmaceutical Technology
Dupixent’s sBLA is supported by data from the Phase III NOTUS study (NCT04456673) and the Phase III BOREAS study (NCT03930732). In November 2023, the companies reported that an interim analysis from the NOTUS trial showed that patients with COPD who were treated with Dupixent demonstrated a 34% reduction in moderate or severe exacerbations at 52 weeks. The published data from the BOREAS trial also showed that Dupixent resulted in a 30% reduction in moderate or severe acute COPD exacerbations over 52 weeks.
Sanofi and Regeneron are also engaging with regulatory bodies in China and the European Union. Dupixent is currently under review as an add-on maintenance treatment in certain adult patients with uncontrolled COPD by two regulatory agencies, namely China’s National Medical Products Administration (NMPA) and the European Commission.
While Dupixent is making strides in COPD, it fell short for the treatment of chronic spontaneous urticaria (CSU) when the FDA rejected the sBLA for the therapy in October 2023, stating that more efficacy data was needed to support Dupixent’s approval in CSU. However, Sanofi and Regeneron plan to resubmit the sBLA, supplemented by data from the Phase III LIBERTY-CUPID Study C trial (NCT04180488). Results from the trial are expected in late 2024.
Although last week, Dupixent was approved as a treatment for chronic spontaneous urticaria (CSU) in patients aged 12 years and older by the Japanese Ministry of Health, Labor and Welfare
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.